mRNA-Based Vaccine Plus Keytruda Reduces the Risk of Melanoma Spread

Adding an experimental mRNA-based vaccine developed by Moderna and Merck & Co to Keytruda reduced the risk that melanoma would spread by 65 percent over treatment with the immunotherapy drug alone, according to a midstage trial.

Study Finds Meningitis Vaccine Shows Promise

According to a new study, a meningitis vaccine tested in two African countries has shown promise in the fight against the disease, eliciting immune responses against five main strains. The Phase III randomized trials were conducted on 1,800 people in the West African nations of Mali and The Gambia. The under-trial NmCV-5 vaccine, developed by […]

CDC Adds COVID-19 Vaccine to Its Routine Immunization Schedule

The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.

Regen BioPharma Files Patent for mRNA Cancer Vaccine

Regen BioPharma has filed a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented mRNA cancer immunotherapeutic vaccine.

First Malaria Vaccine Prequalified by WHO

The World Health Organization has prequalified the first malaria vaccine, RTS,S/AS01 (also known as Mosquirix), manufactured by GSK, bringing it closer to reaching millions more children at risk of malaria.

Study Finds Universal Influenza B Vaccine Induces Broad and Lasting Protection

A study by researchers at Georgia State University’s Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.

Researchers Develop a New mRNA Vaccine to Treat Cancer

U.S. researchers have developed a new mRNA vaccine against cancer that delivers the drug directly to the lymphatic system and simulates a strong immune response.

Study Finds Pfizer’s RSV Vaccine Effective in Preventing Illness in Older Adults

Results of a recent study shows Pfizer’s experimental vaccine for respiratory syncytial virus is nearly 86 percent effective in preventing severe illness in older adults.

Experimental RSV Vaccine Shows Promise in Mice

An experimental vaccine shows promise for protecting mice from the respiratory syncytial virus, the pathogen that most commonly causes the chest infection bronchiolitis in young children.

$11 Million Approved for Vaccine to Prevent Smallpox and Monkeypox

The U.S. Department of Health and Human Services will provide approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS, a vaccine approved to prevent smallpox and monkeypox.